The antimalarial properties of the Ang II-derived synthetic peptides were tested in vivo in two models: (1) experimental cerebral malaria (ECM) established in C57BL/6 mice infected with P. berghei ANKA; and (2) a severe non-cerebral malaria mouse model obtained by infecting BALB/c mice with the same parasite strain. This evidence concerns the gene AGT and cerebral malaria.